Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pyrazinamide

FDA-approved product (tablet, oral), marketed as Pyrazinamide.

Registered studies
50+
Lab records
45
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Pyrazinamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Pulmonary tuberculosis
  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other drugs for treatment of tuberculosis
FDA pharmacologic class
Antimycobacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AK01; FDA class Antimycobacterial

Repurposing investigation

Pyrazinamide is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA17.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli15.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae7.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis13.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 2 of 45 lab records
Open Pyrazinamide in ChEMBL Registered studies below
Show the 45 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-4.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-4.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-4.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pyrazinamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO)

    NCT00495326 · start 2007-12

    Registered record
    Registry ID
    NCT00495326
    Conditions
    Tuberculosis; Aids; Hiv Infections
    Interventions
    Nevirapine based therapy; Efavirenz based therapy; Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2007-12
    Completion
    2011-04
    Enrolment
    570

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Aids; Hiv Infections
    InterventionNevirapine based therapy; Efavirenz based therapy; Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

    NCT00042289 · start 2003-06-09

    Registered record
    Registry ID
    NCT00042289
    Conditions
    HIV Infections
    Interventions
    atazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3; elvitegravir/cobicistat; dolutegravir; tenofovir alafenamide fumarate (TAF); TAF w/cobicistat; TAF w/cobicistat or ritonavir; efavirenz; darunavir/cobicistat; lopinavir/ritonavir dosage #1; atazanavir/ritonavir/tenofovir dosage #1; rifampicin; ethambutol; isoniazid; pyrazinamide; kanamycin; amikacin; capreomycin; moxifloxacin; levoflaxacin; ofloxacin; ethionamide/prothionamide; terizidone/cycloserine; para-aminosalicylic acid (PAS); high dose INH; bedaquiline; clofazamine; delamanid; linezolid; pretomanid; ethinyl estradiol; etonogestrel implant; nevirapine; amprenavir; abacavir; lopinavir/ritonavir dosage #2; indinavir/ritonavir dosage #1; fosamprenavir/ritonavir; lopinavir/ritonavir dosage #3; atazanavir/ritonavir dosage #1; didanosine delayed release (Videx® EC); emtricitabine; tenofovir; nelfinavir dosage #1; tipranavir/ritonavir; lopinavir/ritonavir dosage #4; ralteg
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2003-06-09
    Completion
    2020-09-30
    Enrolment
    1,578

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionatazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3 +45 more
    PhaseNot recorded
    Registry statusCompleted

  • Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis

    NCT00376012 · start 2001-02

    Registered record
    Registry ID
    NCT00376012
    Conditions
    Tuberculosis; Human Immunodeficiency Virus Infections
    Interventions
    Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide); Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2001-02
    Completion
    2008-09
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Human Immunodeficiency Virus Infections
    InterventionAnti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide); Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)
    PhasePhase 3
    Registry statusUnknown

  • A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.

    NCT00000796

    Registered record
    Registry ID
    NCT00000796
    Conditions
    HIV Infections; Tuberculosis
    Interventions
    Cycloserine; Ethionamide; Capreomycin sulfate; Aminosalicylic acid; Streptomycin sulfate; Ethambutol hydrochloride; Amikacin sulfate; Isoniazid; Pyrazinamide; Pyridoxine hydrochloride; Levofloxacin; Rifampin; Clofazimine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1998-10
    Enrolment
    525

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Tuberculosis
    InterventionCycloserine; Ethionamide; Capreomycin sulfate; Aminosalicylic acid +9 more
    PhaseNot applicable
    Registry statusCompleted

  • Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis

    NCT00000950

    Registered record
    Registry ID
    NCT00000950
    Conditions
    HIV Infections; Tuberculosis
    Interventions
    Ethambutol hydrochloride; Isoniazid; Pyrazinamide; Pyridoxine hydrochloride; Rifampin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Tuberculosis
    InterventionEthambutol hydrochloride; Isoniazid; Pyrazinamide; Pyridoxine hydrochloride +1 more
    PhaseNot applicable
    Registry statusCompleted